These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21136179)

  • 1. Borderline resectable pancreatic cancer: what have we learned and where do we go from here?
    Katz MH; Pisters PW; Lee JE; Fleming JB
    Ann Surg Oncol; 2011 Mar; 18(3):608-10. PubMed ID: 21136179
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society.
    Yamada S; Fujii T; Takami H; Hayashi M; Iwata N; Kanda M; Tanaka C; Sugimoto H; Nakayama G; Koike M; Fujiwara M; Kodera Y
    Surgery; 2017 Oct; 162(4):784-791. PubMed ID: 28655416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
    Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
    Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-expanding metal stents (SEMS) for preoperative biliary decompression in patients with resectable and borderline-resectable pancreatic cancer: outcomes in 241 patients.
    Siddiqui AA; Mehendiratta V; Loren D; Kowalski T; Fang J; Hilden K; Adler DG
    Dig Dis Sci; 2013 Jun; 58(6):1744-50. PubMed ID: 23179157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
    Cooper AB; Holmes HM; des Bordes JK; Fogelman D; Parker NH; Lee JE; Aloia TA; Vauthey JN; Fleming JB; Katz MH
    J Am Coll Surg; 2014 Jul; 219(1):111-20. PubMed ID: 24856952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updates on the use of neoadjuvant therapy in borderline resectable pancreatic cancer.
    Chandhok NS; Saif MW
    JOP; 2014 Mar; 15(2):91-4. PubMed ID: 24618425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
    Versteijne E; Vogel JA; Besselink MG; Busch ORC; Wilmink JW; Daams JG; van Eijck CHJ; Groot Koerkamp B; Rasch CRN; van Tienhoven G;
    Br J Surg; 2018 Jul; 105(8):946-958. PubMed ID: 29708592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Borderline resectable pancreatic cancer: pushing the technical limits of surgery.
    Katz MH; Ahmad S; Nelson H
    Bull Am Coll Surg; 2013 Jan; 98(1):61-3. PubMed ID: 23359915
    [No Abstract]   [Full Text] [Related]  

  • 14. [Surgical treatment of pancreatic carcinoma: problems and recent advances].
    Yang YM; Zhao YP
    Zhonghua Wai Ke Za Zhi; 2016 Jun; 54(6):401-403. PubMed ID: 27938571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.
    Barnes CA; Chavez MI; Tsai S; Aldakkak M; George B; Ritch PS; Dua K; Clarke CN; Tolat P; Hagen C; Hall WA; Erickson BA; Evans DB; Christians KK
    Surgery; 2019 Sep; 166(3):277-285. PubMed ID: 31272811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of group B borderline resectable pancreatic cancer: retrospective analysis.
    Oh TG; Chung MJ; Bang S; Park SW; Chung JB; Song SY; Seong J; Kang CM; Lee WJ; Park JY
    Gut Liver; 2014 Sep; 8(5):557-62. PubMed ID: 25228978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial.
    Versteijne E; van Eijck CH; Punt CJ; Suker M; Zwinderman AH; Dohmen MA; Groothuis KB; Busch OR; Besselink MG; de Hingh IH; Ten Tije AJ; Patijn GA; Bonsing BA; de Vos-Geelen J; Klaase JM; Festen S; Boerma D; Erdmann JI; Molenaar IQ; van der Harst E; van der Kolk MB; Rasch CR; van Tienhoven G;
    Trials; 2016 Mar; 17(1):127. PubMed ID: 26955809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controversial issues of neoadjuvant treatment in borderline resectable pancreatic cancer.
    Kang CM; Hwang HK; Choi SH; Lee WJ
    Surg Oncol; 2013 Jun; 22(2):123-31. PubMed ID: 23518243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.
    Rashid OM; Pimiento JM; Gamenthaler AW; Nguyen P; Ha TT; Hutchinson T; Springett G; Hoffe S; Shridhar R; Hodul PJ; Johnson BL; Illig K; Armstrong PA; Centeno BA; Fulp WJ; Chen DT; Malafa MP
    Ann Surg Oncol; 2016 Apr; 23(4):1371-9. PubMed ID: 26661409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to define and manage borderline resectable pancreatic cancer.
    Papavasiliou P; Chun YS; Hoffman JP
    Surg Clin North Am; 2013 Jun; 93(3):663-74. PubMed ID: 23632151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.